Bone Biologics Corp (BBLG) concluded trading on 12/28/23 at a closing price of $6.00, with 7.67 million shares of worth about $45.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -47.55% during that period and on Thursday the price saw a gain of about 29.03%. Currently the company’s 0.34M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 6 times over the past 12 months. They bought 32,100 shares in 5 of the transactions. In 1 selling transactions, insiders dumped 500,137 shares.
Bone Biologics Corp (NASDAQ: BBLG) started trading at $5.90, above $1.25 from concluding price of the previous day. However, the stock later moved at a day high price of 10.55, or with a gain of 29.03%. Stock saw a price change of 89.27% in past 5 days and over the past one month there was a price change of 77.73%. Year-to-date (YTD), BBLG shares are showing a performance of -88.08% which decreased to -87.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.91 but also hit the highest price of $96.00 during that period. The average intraday trading volume for Bone Biologics Corp shares is 146.56K. The stock is currently trading 75.36% above its 20-day simple moving average (SMA20), while that difference is up 50.47% for SMA50 and it goes to -72.03% lower than SMA200.
Holding of mutual funds in the company is about — while other institutional holders and individual stake holders have control over — and — of the stake respectively.
The stock has a current market capitalization of $2.34M. It has posted earnings per share of -$83.03 in the same period. It has Quick Ratio of 3.95 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BBLG, volatility over the week remained 41.72% while standing at 17.39% over the month.
Analysts are in expectations that Bone Biologics Corp (BBLG) stock would likely to be making an EPS of -$5.6 in the current quarter, while forecast for next quarter EPS is -$7.6 and it is -$29.84 for next year. For the current quarter EPS, analysts have given the company a lowest target -$5.6 which is -$5.6 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$43.2 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -60.30% while it is estimated to decrease by -15.48% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Bone Biologics Corp (BBLG)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
